Announcements Trials
Browse Landscape

Phase

Phase 2 58Phase 1/2 22Phase 3 18Phase 1 16Phase NA 3Phase 2/3 3Phase 4 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Lung Neoplasms 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ductal, Breast 2Adenocarcinoma Of Esophagus 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1The Neoadjuvant Therapy 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Seminoma 1Recurrence 1Primary Malignant Neoplasm of Ovary 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1

Interventions

Oxaliplatin 11Docetaxel 8Fluorouracil 6Capecitabine 6Trastuzumab 5Leucovorin 5Drug Therapy 5apatinib 4S 1 (combination) 4Tegafur 3Paclitaxel 3Nivolumab 3Irinotecan 3Cisplatin 3sintilimab 2disitamab vedotin 2Surgical Procedures, Operative 2Standard of Care 2Ramucirumab 2Hyperthermic Intraperitoneal Chemotherapy 2Epirubicin 2vinflunine 1toripalimab 1titanium silicide 1tislelizumab 1taxane 1polysaccharide-K 1pertuzumab 1margetuximab 1gimeracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Stomach Neoplasms × Paclitaxel × Clear all
NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

ALX Oncology Inc.

Phase 2/3 Active not recruiting
127 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06221748 2024-04-03

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RemeGen Co., Ltd.

Phase 2/3 Recruiting
90 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05427383 2023-12-19

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Shanghai JMT-Bio Inc.

Phase 2/3 Recruiting
286 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡